IPA is a biotherapeutic research and technology company that leverages network biology, multi-omics modelling and complex artificial intelligence systems for bioplatform-based antibody discovery —with the first universal solution to enable computation from multiple domains and dimensions of biological knowledge, concurrently.
Recently ranked by one of the pharmaceutical industry’s most trusted, independent market research sources with the highest competitive score for its antibody service portfolio1, the company is comprised of a hybrid of experts and technologies in the science and business of biotherapeutic drug discovery, with highly specialized, full-continuum therapeutic antibody discovery development and services, with new, transformative artificial intelligence technology.
website